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Objective: Innovative treatments are needed for metastatic disease involving the
pleura. NV1020 is a novel, multimutated, replication-restricted herpes simplex virus
under investigation for its ability to selectively kill tumors by means of direct cell
lysis. This study examines NV1020 in a rat model of pleura-based lung cancer.
Methods: Cytotoxicity and viral proliferation were evaluated in vitro by exposure of
the human non–small cell lung cancer cell line A549 to virus. NV1020 was also
tested in an in vivo pleura-based cancer model established by injecting 1  107
A549 cells into the thoracic cavity of nude rats. Intrapleural treatments (1  107
viral particles) were given 3 hours or 3 days after tumor injection to model treatment
of microscopic or macroscopic disease (n 8-9/group). Tumor burden was assessed
at 5 weeks. NV1020 infection and dissemination within the thoracic cavity was
determined by means of immunohistochemistry.
Results: In vitro, at multiplicities of infection (viral particles per tumor cell) of 0.01,
0.1, and 1.0, cell killing of A549 by NV1020 was 66%, 90%, and 97%, respectively,
at 7 days after infection. Viral burst occurred by day 2. Intrapleural treatment was
effective for both the microscopic (P  .001) and macroscopic (P  .05) in vivo
tumor models. Virus was detectable by means of immunohistochemistry in tumors
but not in adjacent normal intrathoracic tissues.
Conclusions: NV1020 is not only highly cytotoxic to the human lung cancer line
A549 in vitro but can be delivered in a clinically relevant fashion to safely and
effectively treat pleura-based tumor in vivo in a rat model.
Metastatic disease of the pleura is a common and significantmanagement problem for the thoracic oncologist. This occursmost frequently in patients with locally advanced or dissem-inated cancer but occasionally occurs as a disease of unknownprimary cause. The pleural tumor itself usually manifests as amalignant effusion but can also present as a pleura-based
mass. The most common causes are lung, breast, ovarian, and lymphoid cancers.1,2
Unfortunately, systemic chemotherapy has a poor response rate in these malignant
tumors. Several chemotherapeutic agents have been used to treat pleural disease by
means of intrapleural administration, with no more than modest success.3,4 As a
result, new therapeutic modalities are needed to control this condition.
Oncolytic viral therapy is an exciting and promising new method of cancer
treatment. Genetically, modified herpes simplex type 1 virus (HSV-1) has been
shown to selectively replicate within and lyse malignant cells while sparing normal
tissue and are under investigation as treatment for tumors of the brain, colon,
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stomach, prostate, ovary, head, and neck, as well as a
peritoneal model of malignant mesothelioma.5-11 NV1020 is
an attenuated, replication-competent HSV-1 virus originally
designed for herpes vaccine studies that is currently being
explored as an oncolytic viral therapy. Multiple genetic
modifications render NV1020 less virulent in normal tissue,
yet it maintains the capacity to infect, replicate within, and
lyse malignant cells. Several genes, including the UL24
gene and one of two copies of the 134.5 gene have been
deleted to attenuate neurovirulence.6,9,12
Several models of pleural metastatic disease have previ-
ously been developed in the mouse that are assessable
mainly by tumor-related mortality.13-15 In the current study
we describe the development of a model of metastatic
pleural disease in the rat that allows assessment of tumor
burden and extent of viral dissemination, as well as mortal-
ity. Using this model, the current study explores the utility




The human lung adenocarcinoma cell line A549 was obtained
from the American Type Culture Collection (Rockville, Md) and
was maintained in Ham’s F-12 medium containing 10% fetal calf
serum, 100 g/mL penicillin, and 100 g/mL streptomycin. Cells
were maintained in a 5% carbon dioxide humidified incubator at
37°C. Cell viability for all experiments was greater than 95%, as
determined by means of trypan blue exclusion.
Virus
NV1020 (gift of Medigene Inc, San Diego, Calif) is an attenuated,
replication-competent derivative of HSV-1.16 NV1020 is a nonse-
lected clonal derivative from R7020, a candidate HSV-1/2 vaccine
strain, obtained from Dr B. Roizman.17 The structure of NV1020
is characterized by a 15-kb deletion encompassing the internal
repeat region, leaving only one copy of the following genes, which
are normally diploid in the HSV-1 genome: ICP0, ICP4, the
latency associated transcripts, and the neurovirulence gene 134.5.
A fragment of HSV-2 DNA encoding several glycoprotein genes
was inserted into this deleted region. In addition, a 700-bp deletion
encompasses the endogenous thymidine kinase locus, which also
prevents the expression of the overlapping transcripts of the UL24
gene. An exogenous copy of the gene encoding HSV-1 thymidine
kinase was inserted under control of the 4 promotor. Virus was
propagated in vero cells and harvested by means of freeze-thaw
lysis to release virus from the cell fraction. Cell lysates were
clarified by means of centrifugation, and viral titers were deter-
mined on vero cells by means of plaque assay. All virus prepara-
tions were formulated in D–phosphate-buffered saline solution
(PBS)–10% glycerin and stored at 80°C.
Animals
All animal work was performed with the prior approval of the
Memorial Sloan-Kettering Institutional Animal Care and Use
Committee. Athymic male rats 6 to 8 weeks old were purchased
from the National Cancer Institute (Bethesda, Md). Animals were
subjected to a 12:12-hour light/dark cycle, housed 2 per cage, and
allowed food and water ad libitum.
In Vitro Cytotoxicity
The ability of NV1020 to infect and lyse A549 cells in vitro was
assessed. Cells were plated at 5  104 cells/well in 12-well plates
(Corning Inc, Corning, NY) and were infected with NV1020 at
multiplicities of infection (MOI) of 0.01, 0.1, and 1.0. Control
wells were treated with culture medium alone. Cell viability was
assessed by counting live cells through trypan blue exclusion at
24-hour intervals carried out to 7 days. All assays were performed
in triplicate.
In Vitro Viral Proliferation
A viral growth curve was established to demonstrate viral repli-
cation in A549 cells. Cells (5  104) were plated in 6-well plates
(Corning Inc) and infected with NV1020 at an MOI of 1.0 (5 
104 plaque-forming units [PFU]). Cells and supernatants were
harvested daily for 5 days after infection. Three cycles of freeze-
thaw lysis were performed, and viral titers were determined by
means of standard plaque assay with vero cells. All infections were
performed in triplicate.
Establishment and Treatment of Pleural Tumor in
Rats
A cellular suspension of A549 was implanted in the thorax of
athymic rats, as previously described.18 Anesthesia was induced by
means of a single intraperitoneal injection of pentobarbital (50
mg/kg). Rats were placed in the right lateral decubitus position.
The left chest was shaved and prepared with 10% povidone-iodine
solution. A 2-cm skin incision was created over the fifth or sixth
intercostal space. Sharp dissection was carried out through the
muscle layers anterior to the latissimus dorsi. A number 10 scalpel
was used to carefully shave away the intercostal muscles, exposing
the parietal pleura without breaching it. The underlying expanding
lung was thereby easily visualized through the thin membrane.
Three hundred microliters of A549 cellular suspension (1  107
cells) was slowly injected through the pleura with a 27-gauge
needle. Puncture of the lung was easily avoided because the needle
tip was clearly observed to be superficial to the lung surface during
injection through the transparent parietal pleura. After injection,
the muscle layer was reapproximated with interrupted 4-0 nylon
sutures, and the skin was closed with surgical staples. Recovery
was observed for 2 hours before the rats were returned to their
cages.
Intrapleural treatment with virus was performed in a similar
fashion either 3 hours or 3 days after tumor implantation. NV1020
(1  107 PFU) was administered in 300 L of PBS. Control
animals were treated with an equal volume of PBS. For intrave-
nous treatment, the same dose of virus was administered in 1 mL
of PBS by means of penile vein injection. Rats were regularly
assessed for weight loss and tachypnea throughout the experimen-
tal period. Rats were killed, and all visible tumor in the chest was
excised to quantify tumor bulk at 5 weeks after implantation. Total
tumor weight was assessed.
In the first experiment the ability of NV1020 to treat free-
floating microscopic disease was assessed. Twenty-seven rats (n
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9/group) were injected with A549 into the pleural space, and chest
incisions were closed. Three hours later, rats were treated with
either intrapleural PBS, intrapleural NV1020, or intravenous
NV1020. Five weeks later, the animals were killed and intrapleural
tumor weight was determined. In a second experiment NV1020
was evaluated for the treatment of macroscopic pleural disease.
Two groups of rats (n 8-9/group) were implanted with A549 and
treated 3 days later. Two additional rats were injected with tumor
and killed at 3 days to verify the presence of macroscopic disease.
Histologic Analysis of the Extent of NV1020 Infection
and Dissemination in Vivo
Control animals with no pleural tumor and animals with 4-week-
old A549 tumors within the pleural cavity were injected with virus
(n  3/group) to assess for viral dissemination in tumor and in
noncancerous tissues. Three days later, rats were killed, and in-
trathoracic tissues were harvested. Tissues (tumor, heart, lung,
chest wall, and diaphragm) were fixed in 4% paraformaldehyde
and embedded in paraffin with a tissue processor (TP1050; Leica
Microsystems, Deerfield, Ill). Eight-micrometer paraffin sections
were stained immunohistochemically to assess the presence of
HSV-1 by using a polyclonal rabbit anti-HSV antibody (No.
PU084-UP; Biogenex, San Ramon, Calif) in conjunction with the
ABC Elite kit (Vector Labs, Burlingame, Calif) detection system.
Sections were counterstained with Gill’s hematoxylin solution,




The oncolytic efficacy of NV1020 against A549 cells in
vitro was assessed. Viable cells remaining over time (as a
fraction of control) are demonstrated in Figure 1. Significant
cell lysis begins 48 hours after infection. By day 7, NV1020
killed 66%, 90%, and 97% of tumor cells at MOI levels of
0.01, 0.1, and 1, respectively. A clear dose-response rela-
tionship exists. Similar results were seen with the human
lung squamous cell H157 (data not shown).
In Vitro Viral Proliferation
Cells were infected at an MOI of 1 (5  104 PFU) to assess
the ability of A549 to permit viral replication. Virions were
recovered from both supernatant and cells and titered daily
over 5 days (Figure 2). By 48 hours, a viral burst occurred,
producing a 17-fold increase in viral titer (8.8  105 PFU).
This burst activity corresponds to the sharp decline in viable
cells observed at day 3 in the cytotoxicity curve.
Treatment in Rat Model of Microscopic Pleural
Tumor
Animals were treated 3 hours after injection of tumor cells
to evaluate the efficacy of NV1020 for the treatment of
free-floating microscopic disease. By 5 weeks, control ani-
mals had bulky disease, with the largest nodules (1-5 mm)
on the pleura and pericardium. In several cases the dia-
phragm was partially replaced with tumor. The internal
chest wall also exhibited large tumor nodules. Smaller nod-
ules were occasionally seen on the surface of the heart and
lungs (1 mm). A nonbloody pleural effusion was present
in 3 of 9 animals in the control group. Disease was limited
to the thoracic cavity. At death, extrathoracic organs (brain,
liver, spleen, kidney, retroperitoneum, and spine) showed
no evidence of macroscopic disease on sectioning. Direct
injection of NV1020 into the pleural cavity significantly
suppressed tumor growth and completely prevented tumor
growth in 5 of 9 animals (Figure 3). Mean  SEM tumor
weight in the control group was 2.07  0.51 g compared
with 0.02  0.01 g in the intrapleural treatment group (P 
Figure 1. In vitro cytotoxicity of NV1020 against A549 cells ex-
pressed as a fraction of control. Cell counts were measured daily
for 7 days. Assays were performed in triplicate, and error bars
indicate SEM.
Figure 2. NV1020 replication in A549 cells after in vitro infection
with an MOI of 1.0 (5  104 PFU). Viral titers were evaluated by
means of standard plaque assay. Assays were performed in
triplicate, and error bars indicate SEM.
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.001). Intravenous therapy, however, had no significant
effect of reducing tumor burden (mean tumor weight,
1.30  0.48 g). Animals in all 3 groups gained weight
throughout the experimental period without exhibiting
tachypnea or other outward signs of distress.
Treatment in a Rat Model of Macroscopic Pleural
Tumor
Two animals were killed 3 days after A549 cells were
injected into the pleural space to document the presence of
tumor implantation and macroscopic pleural disease at 3
days after inoculation. Multiple small (0.5-1.0 mm) nodules
were grossly visible on the pleura, chest wall, and dia-
phragm, as well as within the mediastinal fat. Tissues were
fixed, and sections were stained with hematoxylin and eosin
for microscopic confirmation (Figure 4, A-C). On micro-
scopic evaluation, tumor was also detected in the mediasti-
nal fatty tissue.
Rats inoculated 3 days prior with intrapleural A549 were
treated with either intrapleural NV1020 (1  107 PFU) or
intrapleural PBS to evaluate the ability of the virus to treat
implanted, macroscopic disease. The rats were killed 5
weeks later, and tumor burden was assessed. Animals
treated with intrapleural virus had significantly less tumor
burden than control animals (P  .05, Figure 5). Mean 
SEM tumor weight in the control group was 1.02  0.44 g,
and mean tumor weight in the treated group was 0.23 
0.20 g. A nonbloody pleural effusion developed in 2 of 8
rats in the control group. In the treated group 4 of 9 rats had
no tumor.
Immunohistochemical Analysis of Thoracic Tissues
Three rats were inoculated with A549 cells and injected
with intrapleural NV1020 4 weeks later. Three days after
NV1020 injection, at the peak of viral proliferation (as
determined by prior studies), rats were killed, and intratho-
racic tissues and tumor were harvested.6 In all 3 rats, tumor
specimens displayed immunohistochemical evidence of the
presence of viral antigen (Figure 4, D). Positive staining for
viral antigen progressed beyond the surface to involve cell
layers deep in the tumor. Normal tissues tested were lung,
heart, diaphragm, and internal chest wall. Viral presence
was not detectable in any of these normal tissues in any of
the 3 animals. Of note, the neurovascular bundles in these
organs also did not demonstrate any staining for virus. In
animals that were not administered tumor cells, viral pres-
ence was also undetectable in all of the normal tissues after
viral treatment.
Discussion
Malignant disease of the pleura is associated with a grim
prognosis, with most patients surviving only a few months
after diagnosis.19 The most common cause is lung cancer,
comprising 35% to 40% of all malignant effusions.1,2,20 The
majority of cases are adenocarcinoma by histotype.2 Chem-
ical sclerosing agents are often administered to obliterate
the pleural space to treat the effusions accompanying tumor
at this site that result in shortness of breath, but they do not
address the underlying disease. Interest in intrapleural ad-
ministration of chemotherapeutics has been driven by the
theoretical advantage of treating local and regional disease
in addition to palliating the effusion. Several groups, with
varied success, have explored intrapleural chemotherapy
Figure 3. Mean intrapleural tumor weight in rats treated 3 hours after tumor inoculation. Rats were treated with
intrapleural PBS, intravenous NV1020 (1  107 PFU), or intrapleural NV1020 (1  107 PFU). Error bars indicate SEM.
The P value for the intravenous treated group is .29, and that for the intrapleural group is .001.
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with assorted agents.3,4 None of these cytotoxic agents has
proven as effective for palliation as the sclerosants. In
addition, the disadvantages of pain, fever, organ toxicity,
and high cost have decreased enthusiasm for these treat-
ments. There is clearly a need for the development of novel
therapies for metastatic disease of the pleura.
Biologic therapies are promising alternatives currently
being explored for the treatment of thoracic malignancies.
Gene-replacement therapy (p53 specifically), suicide gene
therapy (using the HSV tk gene and ganciclovir), and im-
munogenetic therapy are some examples of these new ap-
proaches to cancer treatment.21 These approaches have not
yet met with major success. Oncolytic viral therapy, on the
other hand, uses the natural ability of replication-competent
HSV-1 to infect and lyse target cells. Several attenuated
mutants have been developed, which preferentially infect
tumor cells while sparing normal tissue. The theoretical
advantage of using a replication-competent virus is that only
a fraction of tumor cells need be infected initially before the
virus propagates in permissive cancerous tissue.
NV1020 is an HSV-1 oncolytic virus highly attenuated
for neurovirulence yet replication competent in tumor cells.
The basis for this attenuation is not completely understood
but is likely caused by the deletion of several wild-type
genes, including a single copy of 134.5, as well as UL56
and UL24. NV1020 has proven safe in primate studies when
delivered in doses over 10,000 times higher than the known
lethal dose of wild-type HSV-1.12 Several added measures
of safety also exist because of the structure of this virus.
Because NV1020 is a multimutated virus, the chance of
spontaneous reversion is extremely remote.17 Also, because
of the presence of the gene encoding thymidine kinase,
NV1020 would also be susceptible to antiviral chemother-
apy with acyclovir. Indeed, in the current studies viral
dissemination was only found in tumors by means of im-
munohistochemistry. This positive staining was found sev-
eral cell layers deep from the tumor surface, indicating
cell-to-cell spread of viral progeny. There was no immuno-
histochemical evidence of virus in adjacent normal intratho-
racic tissues, specifically heart, lung, diaphragm, and chest
Figure 4. Representative sections of tumor implants evident 3 days after intrapleural tumor inoculation. Shown are
samples from mediastinal fat (A), chest wall (B), and diaphragm (C). (Original magnification 20.) D is a
representative section of pleural tumor from rats treated with intrapleural virus 72 hours earlier. Sections were
analyzed by means of immunohistochemistry with a polyclonal anti-HSV primary antibody. Brown cells are positive
for viral antigen.
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wall. Furthermore, rats displayed no neurologic symptoms,
such as paralysis or ataxia, and gained weight throughout
the experimental period. These data would be consistent
with previous data demonstrating that this and other 134.5
mutant viruses can be injected into many rodent models of
cancer, with only minimal detection of virus in neural tissue
and no discernable neurologic deficits.6,9 Furthermore, the
current virus has been delivered into the brain of primates
sensitive to wild-type virus with much reduced toxicity.12
Two different 134.5 mutant viruses are also delivered by
means of direct injection into brain tumors in human trials,
with no current evidence of viral dissemination in noncan-
cerous tissues.22
With the use of 3 viral concentrations, the human lung
adenocarcinoma cell line A549 proved susceptible to infec-
tion and lysis by NV1020. Even at an MOI of 0.01, NV1020
killed 66% of the cells by day 7. This suggests that repli-
cation and subsequent infection by progeny virions also
occurred. This is similar to the finding of Kucharczuk and
colleagues,10 who found that A549 was susceptible to an-
other HSV-1–based oncolytic virus, HSV-1716. The viral
growth assay confirms that A549 efficiently supports
NV1020 replication, indicating a viral burst at 48 hours after
infection. This correlates with the increase in cell death at
48 to 72 hours seen in the cytotoxicity assay.
Two clinical situations were mimicked by our model to
evaluate the efficacy of NV1020 in vivo. In the first scenario
we set out to treat free tumor cells in the pleural cavity,
simulating a malignant effusion. A tumor cell suspension
was introduced into the pleural cavity, and the animals were
treated 3 hours later through 2 different routes. Intravenous
therapy proved to be ineffective in this experiment. This is
most likely the result of several factors. First, the tumor
cells were certainly not vascularized at this point. Second,
NV1020 is rapidly cleared from the bloodstream after in-
travenous injection,12 leaving little virus to extravasate into
the pleural cavity. It is possible, however, that systemic
delivery might have proven efficacious had our sample size
been greater. Intrapleural regional therapy, on the other
hand, was extremely effective. Direct injection into the
pleural space has the theoretic advantage of increasing the
concentration of virus at the site of disease, thereby maxi-
mizing the therapeutic effect while minimizing systemic
toxicities. This particular experiment demonstrated the ef-
ficacy of NV1020 for the treatment of free-floating tumor
cells in the pleural space and encourages future clinical
testing of this virus in conjunction with resection for ad-
vanced local lung cancer where free pleural shedding of
tumor is likely.
The final common pathway of malignant pleural fluid
formation is impaired lymphatic drainage from the pleural
space.23 This is caused by gross tumor infiltration of parietal
pleural stomata, obstruction of mediastinal nodes, and ob-
struction of lymphatics. This scenario of gross disease is
modeled by our second in vivo experiment, in which ani-
mals were treated 3 days after intrapleural introduction of
tumor. At 3 days, animals have gross tumors on the pleura,
chest wall, and diaphragm, as well as microscopic disease
within the mediastinal fat. These tumor locations are similar
to clinical findings of pleural metastatic lesions in patients.24
We show that NV1020 inhibits progression of gross disease
within the pleural cavity. The results of this experiment, as
expected, were less striking than results obtained in exper-
imental treatment of microscopic disease. It is likely that, on
multiple administrations of virus, a more pronounced effect
might be seen.11 Furthermore, because oncolytic viral ther-
Figure 5. Mean intrapleural tumor weight in rats treated 3 days after tumor inoculation. Rats were treated with
intrapleural PBS or intrapleural NV1020 (1  107 PFU). Error bars indicate SEM. P value with a nonparametric
Wilcoxon test is .046.
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apy works by means of mechanisms distinct from conven-
tional therapies, cancers that are chemoresistant or radiore-
sistant might be susceptible to virus.25
NV1020 efficiently kills human lung cancer lines in vitro
and is effective in reducing tumor burden in a rat model of
pleural cancer. Moreover, NV1020 appears to be safe when
administered through the intrapleural route in rats. These
initial results encourage further studies with NV1020 for the
treatment of pleural cancers, both metastatic and primary.
We thank Yong-Jia You for excellent technical assistance and
Dr Katia Manova for her advice.
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Discussion
Dr Robert J. Ginsberg (Toronto, Ontario, Canada). Was that
a sham experiment?
Dr Ebright. I assume you are asking me about the animal
treatment efficacy experiments. Both experimental and control
animals were administered the same concentration of intrapleural
tumor at day 0. Experimental animals were treated with intrapleu-
ral virus, and control animals were treated with an identical vol-
ume of intrapleural saline solution.
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